Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20985980 | 0.83 | TGFBR1 (0.34) | NPC1RAB9ASMN1; SMN2TGFBR1 | |
| SCHEMBL30490145 | 0.79 | — | — | |
| SCHEMBL20049571 | 0.79 | PRMT5 (0.32) | PRMT5WDR77TGFBR1 | |
| SCHEMBL19781784 | 0.78 | TRPA1 (0.34) | NPC1RAB9ASMN1; SMN2TGFBR1 | |
| SCHEMBL28995735 | 0.73 | TGFBR1 (0.33) | TGFBR1 | |
| SCHEMBL24460464 | 0.72 | PIK3CA (0.39) | NPC1RAB9ASMN1; SMN2TGFBR1AXL | |
| SCHEMBL19781568 | 0.72 | NOS3 (0.33) | NPC1RAB9APRMT5WDR77TGFBR1 | |
| SCHEMBL22072385 | 0.71 | GABRA1 (0.37) | NPC1RAB9ASMN1; SMN2TGFBR1 | |
| SCHEMBL16386458 | 0.69 | TGFBR1 (0.38) | TGFBR1 | |
| SCHEMBL20986029 | 0.68 | UHRF1 (0.38) | NPC1RAB9ASMN1; SMN2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371433-A1 | Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | US | disclosed |
| US-20190263833-A1 | NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-29 | — | — | US | disclosed |
| WO-2018065365-A1 | NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263833-A1 | NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT8 | NPC1 2629/4885RAB9A 2931/4885SMN1; SMN2 3597/4885 |
| US-20210371433-A1 | Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | PRMT5, PRMT1, PRMT8 | NPC1 2590/4885RAB9A 3003/4885SMN1; SMN2 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.